preVIEW: COVID-19

Corpus overview

Overview

MeSH Disease

COVID-19 (37)

Coronavirus Infections (11)

Pneumonia (10)

Fever (10)

Fatigue (5)


HGNC Genes

solute carrier family 17 member 5 (37)

C-reactive protein (37)

interleukin 6 (6)

glutamic--pyruvic transaminase (4)

fibrinogen beta chain (2)


SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    advanced search
    displaying 1 - 10 records in total 37
    records per page




    Results of Favipiravir Combined Treatment in Intensive Care Patients With Covid-19 MESHD

    Authors: Habip Yilmaz; Emre Güner; Murat Altuntas

    doi:10.21203/rs.3.rs-132216/v1 Date: 2020-12-19 Source: ResearchSquare

    Aim: Covid-19 MESHD ( Coronavirus disease 2019 MESHD) is a disease that has already taken place in human history. Although there is still no effective treatment and vaccine protocol, different treatment options are being tried. In this study, it was aimed to determine the basic characteristics and changes in laboratory findings of patients who were hospitalized with the diagnosis of Covid-19 MESHD in the intensive care unit and underwent treatment protocol containing favipiravir.Material and Method: It was carried out with the data of 179 inpatients in an intensive care unit between 01.06.2020 - 30.06.2020. The inclusion criterias of the study are to have a diagnosis of COVID-19 MESHD confirmed by PCR test, to be hospitalized in the intensive care unit, receiving therapy combined with favipravir and to have access to its data through the automation system. According to literature; the sociodemographic characteristics, some basic characteristics and some laboratory findings of the patients were evaluated. Statistical analyzes were performed using the Statistical Package for Social Sciences (SPSS) version 24.0 (IBM Corp .; Armonk, NY, USA).Findings: The average age of the study group is 60.9±16.4 years and 65.9% (n:118) of them are male. According to the clinical classification, more than half (50.8%, n: 91) are included in the "high" clinical classification. The most common chronic disease MESHD is " hypertension MESHD ( HT MESHD)" (42.5%, n:76) and the most common symptom is " fever MESHD" (57.5%, n: 103). While 82.7% (n: 148) have widespread CT (Computed tomography) findings, CPR HGNC ( C-Reactive protein HGNC) positivity rate is 65.4% (n: 117). Statistical significant difference was detected between three measurements of blood urea nitrogen (BUN), aspartat aminotransferase ( AST HGNC), alanin aminotransfrase (ALT), CRP HGNC between the 1st and the 3rd day. Conclusion: Favipiravir demonstrates a proper safety profile. However, its side effects teratogenicity, hyperuricaemia and QTc MESHD (corrected QT interval) prolongation have not yet been adequately studied. It may be safe and tolerable in short-term use, but more evidence is needed to assess the longer-term effects of treatment.

    Association Between Cystatin C HGNC, Cystatin C HGNC Rangeability and Mortality of COVID-19 MESHD Patients With or Without Type 2 Diabetes Mellitus: An Opportunistic Retrospective Analysis

    Authors: Lei Yang; Dou Xu; Yiqing Tan; Bolin Li; Dan Zhu; Jingbo Wang; Hui Sun; Xinglong Liu; Xiao-Pu Zheng; Ling Zhu; Zhongyu Li

    doi:10.21203/rs.3.rs-112220/v1 Date: 2020-11-19 Source: ResearchSquare

    Background: Since December of 2019, novel coronavirus (SARS-CoV-2)-induced pneumonia MESHD ( COVID-19 MESHD) exploded in Wuhan, and rapidly spread throughout China. Patients with COVID-19 MESHD demonstrated quite different appearances and outcomes in clinical manifestations. We aimed to figure out whether risk factors of the cystatin C HGNC (CysC) and the CysC rangeability are influencing the prognosis of COVID-19 MESHD patients with or without type 2 diabetes mellitus MESHD ( T2DM MESHD).Methods: 675 T2DM MESHD patients and 602 non- T2DM MESHD patients were divided into low CysC group, high CysC group and low CysC rangeability group, high CysC rangeability group according to the serum CysC level and the change range of CysC. Demographic characteristics, clinical data and laboratory results of the four groups were collected and analyzed.Results: Our data showed that COVID-19 MESHD patients with high CysC level and CysC rangeability had more organic damage MESHD and higher mortality rate compared to those with low level or low rangeability of CysC. Furthermore, patients with higher CysC level and CysC rangeability also demonstrated higher blood lymphocytes (lymph), C-reactive protein HGNC (CRP), alanine aminotransferase HGNC (ALT), aspartate aminotransferase ( AST HGNC) which may greatly influence disease progression and poor prognosis of COVID-19 MESHD. After adjusting for possible confounders, multivariate analysis revealed that CysC≤0.93mg/dl as a reference, CysC＞0.93mg/dl were significantly associated with the risk of heart failure MESHD (OR=2.401, 95% CI: 1.118–5.156) and all-cause death MESHD (OR=2.734, 95% CI: 1.098-6.811); referring to CysC rangeability≤0, CysC rangeability＞0 significantly associated with all-cause death MESHD (OR=4.029, 95% CI: 1.864-8.706). Further grouped by T2DM MESHD, these associations were stronger in T2DM MESHD than in non- T2DM MESHD.Conclusions: It suggests that CysC level and CysC rangeability contribute to clinical manifestations and may influence the prognosis of COVID-19 MESHD. The CysC is considered as a potential risk factor of the prognosis of COVID-19 MESHD. Special medical care and appropriate intervention should be performed in COVID-19 MESHD patients with elevated CysC during hospitalization and later clinical follow-up, especially for those with T2DM MESHD.

    Laboratory Predictors for COVID-19 MESHD ICU Admissions in a Caribbean Territory.

    Authors: Chavin Gopaul; Dale Ventour; Davlin Thomas

    doi:10.21203/rs.3.rs-103394/v1 Date: 2020-11-05 Source: ResearchSquare

    Introduction. Understanding the symptoms associated with COVID-19 MESHD cases that require intensive care unit (ICU) attention is important in management of the life threatening case of the disease. Method : This study was carried out with the aim of determining the laboratory indicators of ICU admission. Data from 126 COVID-19 MESHD patients (ICU patients, n = 18, Non-ICU, n = 98) were analyzed from a Caribbean Territory.Results: The median age for the non-ICU patients was 59.0 (IQR = 23.5) years while the ICU patients had a median age of 62.5 (IQR = 17.5). The univariate analysis indicted that laboratory indicators that were significantly associated with ICU admission included WBC (P = 0.037), lymphocyte (P = 0.016), LDH (P = 0.002), AST HGNC (P = 0.005) and CRP HGNC (P = 0.0001). However, multivariate analysis that included WBC, neutrophil, lymphocyte, PLT, AST HGNC, LDH, ALT, and CRP HGNC indicated that only AST HGNC was associated with high odds of patients being admitted to ICU (OR .002, 95% CI 0.000-.004, P = 0.017). Statistically significant area under the curve (AUC) were obtained for Neutrophil (AUC = 0.704, P = 0.007), CRP HGNC (AUC = 0.81, p= 0.00) and LDH (AUC=0.766, P= 0.00) and AST HGNC (AUC= 0.729, P= 0.003). Conclusion: The findings indicate that neutrophils, AST HGNC and LDH’s ROC curves are good tests while CRP HGNC curve is a very good test. However, lymphocyte curve is a poor test for determining COVID-19 MESHD patient for ICU admission. Neutrophil, AST HGNC, LDH and CRP HGNC are suitable predictors of COVID-19 MESHD patients that should receive ICU care

    Covid-19 MESHD fatality prediction in people with diabetes and prediabetes using a simple score at hospital admission

    Authors: Harald Sourij; Faisal Aziz; Alexander Braeuer; Christian Ciardi; Martin Clodi; Peter Fasching; Mario Karolyi; Alexandra Kautzky-Willer; Carmen Klammer; Oliver Malle; Abderrahim Oulhaj; Erich Pawelka; Slobodan Peric; Claudia Ress; Caren Sourij; Lars Stechemesser; Harald Stingl; Thomas Stulnig; Norbert Tripolt; Michael Wagner; Peter Wolf; Andreas Zitterl; Susanne Kaser

    doi:10.1101/2020.11.02.20224311 Date: 2020-11-04 Source: medRxiv

    AIM We assessed predictors of inhospital mortality in people with prediabetes MESHD and diabetes MESHD hospitalized for COVID19 MESHD infection and developed a risk score for identifying those at the highest risk of a fatal outcome. MATERIALS AND METHODS A combined prospective and retrospective multicenter cohort study was conducted in 10 sites in Austria on 247 people with diabetes MESHD or newly diagnosed prediabetes MESHD, who were hospitalised for COVID19 MESHD. The primary outcome was inhospital mortality and predictor variables at the time of admission included clinical data, comorbidities of diabetes MESHD or laboratory data. Logistic regression analyses were performed to identify significant predictors and develop a risk score for inhospital mortality. RESULTS The mean age of people hospitalized (n=238) for COVID-19 MESHD was 71.1{+/-}12.9 years, 63.6% were males, 75.6% had type 2 diabetes MESHD, 4.6% had type 1 diabetes MESHD, and 19.8% had prediabetes MESHD. The mean duration of hospital stay was 18{+/-}16 days, 23.9% required ventilation therapy, and 24.4% died in the hospital. Mortality rate in people with diabetes MESHD was numerically higher (26.7%) as compared to those with prediabetes MESHD (14.9%) but without statistical significance (p=0.128). A score including age, arterial occlusive disease MESHD, CRP HGNC, eGFR HGNC and AST HGNC levels at admission predicted inhospital mortality with a Cstatistics of 0.889 (95%CI: 0.837-0.941) and calibration of 1.000 (p=0.909). CONCLUSIONS The inhospital mortality for COVID-19 MESHD was high in people with diabetes MESHD and not significantly different to the risk in people with prediabetes MESHD. A risk score using five routinely available patient parameters demonstrated excellent predictive performance for assessing inhospital mortality.

    Risk Factors Analysis of COVID-19 MESHD Patients with ARDS MESHD and Prediction Based on Machine Learning

    Authors: Wan Xu; Nan-Nan Sun; Hai-Nv Gao; Zhi-Yuan Chen; Ya Yang; Bin Ju; Ling-Ling Tang

    doi:10.21203/rs.3.rs-77820/v2 Date: 2020-09-15 Source: ResearchSquare

    COVID-19 MESHD is a newly emerging infectious disease MESHD, which is generally susceptible to human beings and has caused huge losses to people's health. Acute respiratory distress syndrome MESHD ( ARDS MESHD) is one of the common clinical manifestations of severe COVID-19 MESHD and it is also responsible for the current shortage of ventilators worldwide. This study aims to analyze the clinical characteristics of COVID-19 MESHD ARDS MESHD patients and establish a diagnostic system based on artificial intelligence (AI) method to predict the probability of ARDS in COVID-19 MESHD patients. We collected clinical data of 659 COVID-19 MESHD patients from 11 regions in China. The clinical characteristics of the ARDS group and no-ARDS group of COVID-19 MESHD patients were elaborately compared and both traditional machine learning algorithms MESHD and deep learning-based method were used to build the prediction models. Results indicated that the median age of ARDS MESHD patients was 56.5 years old, which was significantly older than those with non-ARDS by 7.5 years. Male and patients with BMI>25 were more likely to develop ARDS MESHD. The clinical features of ARDS MESHD patients included cough (80.3%), polypnea (59.2%), lung consolidation (53.9%), secondary bacterial infection MESHD (30.3%), and comorbidities such as hypertension MESHD (48.7%). Abnormal biochemical indicators such as lymphocyte count, CK, NLR, AST HGNC, LDH, and CRP HGNC were all strongly related to the aggravation of ARDS. Furthermore, through various AI methods for modeling and prediction effect evaluation based on the above risk factors, decision tree achieved the best AUC, accuracy, sensitivity and specificity in identifying the mild patients who were easy to develop ARDS MESHD, which undoubtedly helped to deliver proper care and optimize use of limited resources.

    Sex Differences in Clinical Characteristics and Risk Factors for Disease Severity of Hospitalized Patients with COVID-19 MESHD in Beijing

    Authors: Jingjing Wang; Yunjuan Su; Qi Wang; Ying Cao; Aibin Wang; Rui Ding; Wen Xie

    doi:10.21203/rs.3.rs-76948/v1 Date: 2020-09-13 Source: ResearchSquare

    Background: Recent studies reported that sex differences in patients with coronavirus disease-2019 ( COVID-19 MESHD). However the predictive value of sex differences in disease severity were less studied by previous scholars. Methods: All adults (≥18 years) diagnosed with COVID-19 MESHD and admitted to Beijing Ditan Hospital, Capital Medical University (admission date from January 13 to March 19, 2020) were included in samples. Data analyzed in this study included epidemiological, demographic, comorbidities, initial symptoms and signs, laboratory findings, imaging study, disease severity and in-hospital mortality. Results: A total of 185 inpatients were enrolled in the study, among whom 95 patients are males (51.4%). The mean age of all patients was 41 years. Based on the hospital record, the duration from symptoms initiation to hospital admission was longer for men than that for women. Moreover, the mean BMI of males was relatively higher compared to females (25.45vs22.29, p<.001). In addition, the proportion of male patients with CHD, NAFLD, smoking and drinking history was higher than females. During the hospital stay, compared to female patients, male patients were more prone to develop symptoms such as high fever, cough MESHD, and chill. Higher levels of AST HGNC, CK, CRP HGNC and FIB were also observed in male patients. Following this fact, more patients with abnormal CT activities, severe and critical symptoms were developed in male group than females. However, there was no difference in complications and outcome between two groups. By analyzing data comprehensively, we found out that age (analyzed in quartiles, OR: 1.087; 95% CI: 1.038–1.139; p <.001) and BMI (OR: 1.250; 95% CI: 1.046–1.493; p =.014) could be used to help predict disease severity. Conclusions: In this cohort of hospitalized patients in Beijing, male patients developed more clinical symptoms, obtained more abnormal laboratory test results, and showed higher rates in severity of COVID-19 MESHD. Other than that, the severity of COVID-19 MESHD was positively correlated with age and BMI independently. 

    Crucial Laboratory Parameters in Severe COVID-19 MESHD Infection: A Systematic Review and Meta-Analysis

    Authors: Maryam Honardoost; Leila Janani; Zahra Emami; Rokhsareh Aghili; Mohammad Ebrahim Khamseh

    id:10.20944/preprints202009.0063.v1 Date: 2020-09-03 Source: Preprints.org

    Aim: Abnormal laboratory findings have been shown to be associated with severe COVID-19 MESHD. However, all aspects of this association have not been reviewed systematically. Therefore, the aim of this meta-analysis was to explore crucial laboratory parameters in severe COVID-19 MESHD infection. Methods: We performed the literature review of scientific articles indexed in electronic databases. Scientific search engines were used to perform the electronic literature search. After the removal of duplicates and selection of articles of interest, 30 studies were eligible to include. If heterogeneity was high (I2>50%), a random-effects model was applied to combine the data. Otherwise, a fixed-effects model was used.Results: A total of 5586 individuals were assessed (1555 patients with severe COVID-19 MESHD infection and 3452 with non-severe infection). Platelets, lymphocytes and serum albumin were significantly lower in severe patients while other biochemical and immunological parameters including prothrombin time, ALT, AST HGNC, total bilirubin, LDH, procalcitonin, CRP HGNC, IL-6 HGNC, and IgA were significantly higher in patients with severe infection. Neutrophil and monocyte counts as well as hemoglobin level, D-dimer, hypersensitive troponin I, IL-2R HGNC, IgG and IgM levels were different between two groups; however, the difference was not statistically significant (All P-values >0.05). Conclusions: Lymphopenia MESHD, elevated liver enzymes, and high levels of inflammatory biomarkers are associated with severe COVID-19 MESHD infection.

    Viral shedding and immunological features of children COVID-19 MESHD patients

    Authors: Yang Yang; Haixia Zheng; Ling Peng; Jinli Wei; Yanrong Wang; Xiaohe Li; Bo Peng; Shisong Fang; Mingxia Zhang; Hui Liu; Yanjie Li; Kai Feng; Li Xing; Jun Wang; Mengli Cao; Fuxiang Wang; Yingxia Liu; Lei Liu; Jing Yuan

    doi:10.1101/2020.08.25.20181446 Date: 2020-08-31 Source: medRxiv

    Abstract Background SARS-CoV-2 could infect people at all ages, and the viral shedding and immunological features of children COVID-19 MESHD patients were analyzed. Methods Epidemiological information and clinical data were collected from 35 children patients. Viral RNAs in respiratory and fecal samples were detected. Plasma of 11 patients were collected and measured for 48 cytokines. Results 40% (14/35) of the children COVID-19 MESHD patients showed asymptomatic infections, while pneumonia shown by CT scan occurred in most of the cases (32/35, 91.43%). Elevated LDH, AST HGNC, CRP HGNC, neutropenia, leukopenia, lymphopenia and thrombocytopenia occurred in some cases, and CD4 HGNC and CD8 HGNC counts were normal. A total of 22 cytokines were significantly higher than the healthy control, and IP-10 HGNC, IFN-2 of them in children were significantly lower than the adult patients. Meanwhile, MCP-3 HGNC, HGF HGNC, MIP-1 HGNC, and IL-1ra HGNC were similar or lower than healthy control, while significantly lower than adult patients. Viral RNAs were detected as early as the first day after illness onset (d.a.o) in both the respiratory and fecal samples. Viral RNAs decreased as the disease progression and mostly became negative in respiratory samples within 18 d.a.o, while maintained relatively stable during the disease progression and still detectable in some cases during 36~42 d.a.o. Conclusion COVID-19 MESHD in children was mild, and asymptomatic infection was common. Immune responses were relatively normal in children COVID-19 MESHD patients. Cytokine storm also occurred in children patients, while much weaker than adult patients. Positive rate of viral RNAs in fecal samples was high, and profile of viral shedding were different between respiratory and gastrointestinal tract.

    The association between clinical laboratory data and chest CT findings explains disease severity in a large Italian cohort of COVID-19 MESHD patients.

    Authors: Simone Canovi; Giulia Besutti; Efrem Bonelli; Valentina Iotti; Marta Ottone; Laura Albertazzi; Alessandro Zerbini; Pierpaolo Pattacini; Paolo Giorgi Rossi; Rossana Colla; Tommaso Fasano; Reggio Emilia COVID-19 Working Group

    doi:10.21203/rs.3.rs-65304/v1 Date: 2020-08-25 Source: ResearchSquare

    Background: Laboratory data and computed tomography (CT) have been used during the COVID-19 MESHD COVID-19 MESHD pandemic, mainly to determine patient prognosis and guide clinical management. The aim of this study was to evaluate the association between CT findings and laboratory data in a cohort of COVID-19 MESHD patients.Methods: This was an observational cross-sectional study including consecutive patients presenting to the Reggio Emilia (Italy) province emergency rooms for suspected COVID-19 MESHD for one month during the outbreak peak, who underwent chest CT scan and laboratory testing at presentation and resulted positive for SARS-CoV-2.Results: Included were 866 patients. Total leukocytes, neutrophils, C-reactive protein HGNC ( CRP HGNC), creatinine, AST HGNC, ALT and LDH increase with worsening parenchymal involvement; an increase in platelets was appreciable with the highest burden of lung involvement. A decrease in lymphocyte counts paralleled worsening parenchymal extension, along with reduced arterial oxygen partial pressure and saturation. After correcting for parenchymal extension, ground-glass opacities were associated with reduced platelets and increased procalcitonin, consolidation with increased CRP HGNC and reduced oxygen saturation.Conclusions: Pulmonary lesions induced by SARS-CoV-2 infection MESHD were associated with raised inflammatory response, impaired gas exchange and end-organ damage. These data suggest that lung lesions MESHD probably exert a central role in COVID-19 MESHD pathogenesis and clinical presentation.

    Clinical, Laboratory, and Imaging Features of 148 Patients with COVID-19 MESHD in Bushehr: A Report from the South of Iran

    Authors: Mohsen Keshavarz; Ahmad Tavakoli; Sareh Zanganeh; Mohammad Javad Mousavi; Katayoun Vahdat; Mehdi Mahmudpour; Iraj Nabipour; Amir Hossein Darabi; Saeid Keshmiri

    doi:10.1101/2020.08.11.20172692 Date: 2020-08-14 Source: medRxiv

    Aim: To investigate clinical characteristics, laboratory findings, and imaging features of patients confirmed with COVID-19 MESHD in Bushehr, a southern province of Iran. Method: During April 29th to May 30th 2020, a total of 148 patients confirmed with COVID-19 MESHD infection were admitted to three hospitals in Bushehr province, assigned by the Iranian Ministry of Health. Results: The most common coexisting disease was type 2 diabetes MESHD. Levels of ESR, CRP HGNC, LDH, and AST HGNC among inpatients were higher than the outpatients (P<0.05). There were significant differences in the levels of creatinine and BUN between elderly and non-elderly patients (P<0.05). Conclusion: Patients with comorbidities and elderly patients are at increased risk of severe progression of COVID-19 MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources

Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.

Contact | Legal Notice